Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment (NCT05213598)
Natural History of Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
π©Ί Plain-English Summary (8th-Grade Level)
Background: In Fontan Associated Liver Disease (FALD), congestion of blood in the liver causes cirrhosis. This condition can cause death. Researchers want to understand what triggers this process and find new treatments for it. Objective: To understand how long-term congestion of blood in the liver causes liver scarring that eventually leads to cirrhosis. Eligibility: People aged 18 and older who are at risk of developing FALD from the Fontan procedure. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Liver ultrasound. This uses sound waves to take pictures of the body. Participants will have an outpatient visit within 12 weeks after screening. Within 24 weeks later, they will have a 3-day hospital stay. About 2 weeks later, they will have a follow-up visit. Visits will include repeats of the screening tests and: Heart tests Stool collection Questionnaires MRI of the liver. Participants will lie on a bed that slides in and out of the scanner. They will receive a contrast agent injected into a vein. While in the scanner, they will also have an MRCP to view the bile ducts and the pancreatic duct. Fibroscan exam. This is an ultrasound that uses a special probe to look at the toughness of the liver. Upper endoscopy. This uses a thin scope to look inside the upper digestive tract. Liver biopsy. This will be taken through large vein in the neck or through the chest. Just before the biopsy, participants will have pressure measurements inside their liver. For this, a catheter will be inserted into a neck vein and guided into the liver.
Who can join: Review the eligibility criteria below.
Location: National Institutes of Health Clinical Center β Bethesda, Maryland
Age range: 18 Years to 100 Years
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- National Institutes of Health Clinical Center β Bethesda, Maryland
π Contact the Study Coordinator
Phone: (301) 435-6125
Email: erivera@cc.nih.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Congenital Heart Disease
- Technical Development for Pediatric Cardiovascular MRI β Washington D.C., District of Columbia
- Harmony TPV Post-Approval Study β Birmingham, Alabama
- The Medtronic Harmonyβ’ Transcatheter Pulmonary Valve Clinical Study β Los Angeles, California
- Autus Valve Pivotal Study β Los Angeles, California
- Peer Coaching Intervention in Young Adults With Congenital Heart Disease β Durham, North Carolina
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure β Toronto, Ontario
Explore by condition: All Congenital Heart Disease clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.